Ophthalmic formulation

Abstract

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein le is a linear or branched C 9 -C 33 alkyl or a linear or branched C 9 -C 33 alkenyl with 1 to 4 double bonds; R 2 is a linear or branched C 9 -C 19 alkyl or a linear or branched C 9 -C 19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

1 .- 24 . (canceled) 
     
     
         25 . An ophthalmic formulation comprising a compound of formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R1 is a linear or branched C9-C33 alkyl or a linear or branched C9-C33 alkenyl with 1 to 4 double bonds; 
         R2 is a linear or branched C9-C19 alkyl or a linear or branched C9-C19 alkenyl with 1 to 4 double bonds; 
         and an ophthalmologically acceptable carrier. 
       
     
     
         26 . An ophthalmic formulation according to  claim 25 , wherein HOOC—R1— is selected from the group consisting of: capryl (C10:0), lauryl (C12:0), myristyl (C14:0), palmityl (C16:0), stearyl (C18:0), oleoyl (C18:1), linoleoyl (ω6) (C18:2), and linoleoyl (ω3) (C18:3). 
     
     
         27 . An ophthalmic formulation according to  claim 26 , wherein R2 is linear or branched C17 alkyl or linear or branched C17 alkenyl with 1 or 2 double bonds. 
     
     
         28 . An ophthalmic formulation according to  claim 26 , wherein R2 is linear or branched C19 alkenyl with 4 double bonds. 
     
     
         29 . An ophthalmic formulation according to any  claim 26 , wherein the compound of formula (I) is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         30 . A method for the treatment of dry eye comprising topically administering to the eye of a subject in need thereof a therapeutically effective amount of a compound according to  claim 29 . 
     
     
         31 . Use of a compound of formula (I) as defined in  claim 25  in the manufacture of an ophthalmic formulation for the treatment of dry eye.